Harrow IP

Harrow is a leading ophthalmic-focused pharmaceutical company based in North America that specializes in the discovery, development, and commercialization of innovative therapies for eye care. The company's portfolio features a robust selection of FDA-approved branded products, including IHEEZO for ocular anesthesia, VEVYE for dry eye disease, and TRIESENCE for ocular inflammation. In addition to its branded assets, Harrow operates ImprimisRx, one of the largest ophthalmic compounding businesses in the United States, providing customized pharmaceutical solutions to physicians and patients. Through strategic acquisitions, such as the 2023 purchase of several ophthalmic products from Novartis, Harrow has established itself as a major player in the specialty pharmaceutical market. The company is dedicated to improving patient access to affordable and effective treatments for a wide range of ophthalmic conditions.